International
The Morning Science

What science found today

‹
 

Research

Key immune driver of pancreatic cancer points to combination treatment for slowing progression

Medical Xpress ·

Key immune driver of pancreatic cancer points to combination treatment for slowing progression

The Brief

  • Researchers at MD Anderson Cancer Center report that the inflammatory protein IL-18 helps pancreatic tumours grow and evade the immune system.
  • The findings identify IL-18 as a potential therapeutic target for pancreatic cancer.
  • The story points to a combination treatment approach for slowing disease progression.

Why it matters

It identifies a specific immune signalling protein as a possible drug target in pancreatic cancer, a disease with limited treatment options, which may guide future combination therapy research.

Who’s affected

  • pancreatic cancer researchers
  • oncology clinicians and drug developers

Researchers from The University of Texas MD Anderson Cancer Center have discovered that the IL-18 inflammatory protein helps pancreatic tumors grow and evade the immune system, highlighting its potential as a therapeutic target for pancreatic cancer.

Timeline

  1. Medical Xpress reports MD Anderson findings on IL-18 in pancreatic tumour growth

  2. Medical Xpress - latest medical and health news stories

    Key immune driver of pancreatic cancer points to combination treatment for slowing progression

How do you feel about this?

0 Comments